ProPhase Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . ProPhase Labs
PRPH Stock  USD 0.17  0.01  6.25%   
ProPhase Labs' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ProPhase Labs' valuation are provided below:
Gross Profit
987 K
Market Capitalization
786.3 K
Enterprise Value Revenue
1.5901
Revenue
5.1 M
Earnings Share
(19.80)
We have found one hundred twenty available trending fundamental ratios for ProPhase Labs, which can be analyzed and compared to other ratios and to its competitors. Traders should compare all of ProPhase Labs recent fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 53.2 M. Enterprise Value is estimated to decrease to about 50 M

ProPhase Labs Total Revenue

7.4 Million

Check ProPhase Labs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProPhase Labs' main balance sheet or income statement drivers, such as Interest Expense of 4 M, Selling General Administrative of 32.4 M or Total Revenue of 7.4 M, as well as many indicators such as Price To Sales Ratio of 2.33, Dividend Yield of 0.13 or PTB Ratio of 2.15. ProPhase financial statements analysis is a perfect complement when working with ProPhase Labs Valuation or Volatility modules.
  
Build AI portfolio with ProPhase Stock
Check out the analysis of ProPhase Labs Correlation against competitors.
For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.

ProPhase Labs Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets36.6 M72.7 M37.5 M
Slightly volatile
Total Current Liabilities38.8 M37 M12.2 M
Slightly volatile
Total Stockholder Equity8 M8.5 M19.3 M
Slightly volatile
Property Plant And Equipment Net14 M13.4 M6.3 M
Slightly volatile
Accounts Payable16.6 M15.8 M4.7 M
Slightly volatile
Cash579.7 K610.2 K2.7 M
Very volatile
Non Current Assets Total39.3 M37.4 M15.4 M
Slightly volatile
Cash And Short Term Investments579.7 K610.2 K5.6 M
Pretty Stable
Net Receivables24.2 M23.1 M13.4 M
Slightly volatile
Common Stock Shares Outstanding1.6 M1.7 M10 M
Slightly volatile
Liabilities And Stockholders Equity36.6 M72.7 M37.5 M
Slightly volatile
Non Current Liabilities Total28.6 M27.3 M8.6 M
Slightly volatile
Inventory977.3 K1 M2.3 M
Very volatile
Other Stockholder Equity79.6 M75.8 M33.4 M
Slightly volatile
Total Liabilities67.4 M64.2 M20.5 M
Slightly volatile
Property Plant And Equipment Gross24.9 M23.7 M8.4 M
Slightly volatile
Total Current Assets27.7 M35.2 M24 M
Slightly volatile
Other Current Liabilities3.9 M7.3 M4.1 M
Very volatile
Common Stock Total Equity11.9712.6441.9 K
Slightly volatile
Common Stock19.7 K20.7 K449.4 K
Slightly volatile
Property Plant Equipment12.5 M11.9 M5.9 M
Slightly volatile
Short and Long Term Debt Total29.7 M28.3 M8.7 M
Slightly volatile
Current Deferred Revenue1.7 M1.5 M1.9 M
Slightly volatile
Net Tangible Assets50.8 M48.4 M23.1 M
Slightly volatile
Capital Surpluse58.8 M70.9 M56 M
Slightly volatile
Other Liabilities1.5 M1.5 M570 K
Slightly volatile
Non Current Liabilities Other5.5 M5.2 M2.1 M
Slightly volatile
Long Term Debt Total6.3 M11.5 M6.9 M
Slightly volatile
Net Invested Capital41 M25.5 M35.1 M
Pretty Stable
Capital Stock18.1 K26.4 K16 K
Slightly volatile
Capital Lease Obligations7.7 M11.2 M6 M
Slightly volatile

ProPhase Labs Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative32.4 M34.1 M15.7 M
Slightly volatile
Total Revenue7.4 M7.8 M26.2 M
Pretty Stable
Other Operating Expenses36.2 M52.2 M33.7 M
Slightly volatile
Total Operating Expenses46.5 M44.3 M21.1 M
Slightly volatile
Depreciation And Amortization8 M7.6 M2.5 M
Slightly volatile
Cost Of Revenue7.6 M8 M14.9 M
Pretty Stable
Research Development507.9 K534.6 K787.9 K
Slightly volatile
Selling And Marketing Expenses1.7 M1.7 M355.5 M
Slightly volatile
Non Operating Income Net Other74.9 K71.3 K54.5 K
Slightly volatile
Non Recurring2.9 M3.2 M3.5 M
Slightly volatile
Reconciled Depreciation8 M7.6 M2.4 M
Slightly volatile

ProPhase Labs Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow1.4 M1.4 M3.3 M
Very volatile
End Period Cash Flow579.7 K610.2 K2.8 M
Pretty Stable
Stock Based Compensation4.4 M4.2 M1.7 M
Slightly volatile
Depreciation8 M7.6 M2.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.332.4518.7935
Slightly volatile
Dividend Yield0.130.140.1411
Slightly volatile
PTB Ratio2.152.2614.1686
Slightly volatile
Days Sales Outstanding1 K973297
Slightly volatile
Book Value Per Share4.214.4312.6014
Slightly volatile
Average Payables591.3 K755.1 K859.9 K
Slightly volatile
Stock Based Compensation To Revenue0.510.480.1198
Slightly volatile
Capex To Depreciation0.120.13641.0374
Slightly volatile
PB Ratio2.152.2614.1686
Slightly volatile
EV To Sales6.196.5119.4391
Slightly volatile
Inventory Turnover3.675.455.2399
Slightly volatile
Days Of Inventory On Hand13269.3395.1947
Slightly volatile
Payables Turnover0.550.588.1891
Slightly volatile
Sales General And Administrative To Revenue5.295.041.3389
Slightly volatile
Average Inventory5.7 M4.5 M4.2 M
Very volatile
Research And Ddevelopement To Revenue0.070.10.0475
Very volatile
Capex To Revenue0.130.120.0495
Slightly volatile
Cash Per Share0.390.413.8486
Pretty Stable
Days Payables Outstanding684651164
Slightly volatile
Intangibles To Total Assets0.220.210.143
Slightly volatile
Current Ratio1.041.13.8549
Pretty Stable
Receivables Turnover0.370.392.8662
Slightly volatile
Shareholders Equity Per Share4.214.4312.5544
Slightly volatile
Debt To Equity3.163.011.0024
Slightly volatile
Capex Per Share0.50.430.718
Slightly volatile
Average Receivables4.2 M3.1 M3.6 M
Slightly volatile
Revenue Per Share3.884.0816.9206
Pretty Stable
Interest Debt Per Share13.8313.176.5853
Slightly volatile
Debt To Assets0.370.350.2431
Slightly volatile
Graham Number96.9792.3577.4799
Slightly volatile
Operating Cycle1.1 K1 K379
Slightly volatile
Price Book Value Ratio2.152.2614.1686
Slightly volatile
Days Of Payables Outstanding684651164
Slightly volatile
Ebt Per Ebit1.071.260.9722
Very volatile
Company Equity Multiplier8.127.742.7437
Slightly volatile
Long Term Debt To Capitalization0.580.550.298
Slightly volatile
Total Debt To Capitalization0.730.690.3601
Slightly volatile
Debt Equity Ratio3.163.011.0024
Slightly volatile
Quick Ratio1.01.063.3637
Pretty Stable
Cash Ratio0.02310.02430.617
Slightly volatile
Cash Conversion Cycle505481229
Slightly volatile
Days Of Inventory Outstanding13269.3395.1947
Slightly volatile
Days Of Sales Outstanding1 K973297
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.850.951.1673
Very volatile
Price To Book Ratio2.152.2614.1686
Slightly volatile
Fixed Asset Turnover0.640.677.2619
Slightly volatile
Debt Ratio0.370.350.2431
Slightly volatile
Price Sales Ratio2.332.4518.7935
Slightly volatile
Asset Turnover0.120.10710.8221
Slightly volatile
Price Fair Value2.152.2614.1686
Slightly volatile

ProPhase Labs Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap53.2 M56 M55.6 M
Slightly volatile
Enterprise Value50 M52.6 M51.4 M
Slightly volatile

ProPhase Fundamental Market Drivers

Forward Price Earnings10.0908
Cash And Short Term Investments678 K

ProPhase Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About ProPhase Labs Financial Statements

Investors use fundamental indicators, such as ProPhase Labs' revenue or net income, to determine how well the company is positioned to perform in the future. Although ProPhase Labs' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue1.5 M1.7 M
Total Revenue7.8 M7.4 M
Cost Of Revenue8 M7.6 M
Stock Based Compensation To Revenue 0.48  0.51 
Sales General And Administrative To Revenue 5.04  5.29 
Research And Ddevelopement To Revenue 0.10  0.07 
Capex To Revenue 0.12  0.13 
Revenue Per Share 4.08  3.88 
Ebit Per Revenue(6.56)(6.23)

Currently Active Assets on Macroaxis

VTIVanguard Total Stock
RIOTRiot Blockchain
TSLATesla Inc
VVisa Class A
SCHDSchwab Dividend Equity
When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:
How To Invest In ProPhase
Details
Is ProPhase Stock a good investment?
Details
What is ProPhase Labs' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of ProPhase Labs Correlation against competitors.
For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is there potential for Pharmaceuticals market expansion? Will ProPhase introduce new products? Factors like these will boost the valuation of ProPhase Labs. Anticipated expansion of ProPhase directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.95)
Earnings Share
(19.80)
Revenue Per Share
1.402
Quarterly Revenue Growth
(0.38)
Return On Assets
(0.23)
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between ProPhase Labs' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ProPhase Labs should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, ProPhase Labs' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY